Colorectal Cancer - Pipeline Review, H1 2018 - ResearchAndMarkets.com

September 28, 2018

DUBLIN--(BUSINESS WIRE)--Sep 28, 2018--The “Colorectal Cancer - Pipeline Review, H1 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 27, 132, 157, 16, 185, 32 and 14 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 23, 9, 1, 30 and 3 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered

1. Introduction

2. Colorectal Cancer - Overview

3. Colorectal Cancer - Therapeutics Development

4. Colorectal Cancer - Therapeutics Assessment

5. Colorectal Cancer - Companies Involved in Therapeutics Development

6. Colorectal Cancer - Drug Profiles

7. Colorectal Cancer - Dormant Projects

8. Colorectal Cancer - Discontinued Products

9. Colorectal Cancer - Product Development Milestones

Companies Featured

3-V Biosciences Inc 3SBio Inc 4SC AG Allinky Biopharma Amarin Corp Plc amcure GmbH Amgen Inc ARMO Biosciences Inc Bionomics Ltd Bionovis SA Biotecnol Ltd Biothera Pharmaceutical Inc Cleveland BioLabs Inc Idera Pharmaceuticals Inc Ignyta Inc Johnson & Johnson Karyopharm Therapeutics Inc Kazia Therapeutics Ltd Kura Oncology Inc Laboratorio ELEA SACIF y A LipoMedix Pharmaceutical Inc Loxo Oncology Inc Luye Pharma Group Ltd Merck & Co Inc Merck KGaA Merus NV MetaMax Ltd Millennium Pharmaceuticals Inc Mirati Therapeutics Inc Moderna Therapeutics Inc Molecular Partners AG SynDevRx Inc TaiwanJ Pharmaceuticals Co Ltd Takeda Pharmaceutical Co Ltd and many, many more...

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/cc3dwt/colorectal_cancer?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180928005647/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Colon Cancer Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/28/2018 05:44 PM/DISC: 09/28/2018 05:44 PM


Update hourly